Indo Amines Ltd

- There is no explicit mention of any immediate or planned new fundraising through debt or equity in the transcript. - The company currently has a consolidated debt of around Rs. 125 crore, including Rs. 80 crore as working capital. - They have ongoing CAPEX plans with investments around Rs. 30 crore for the current year and around Rs. 10 crore planned for the next year, totaling approximately Rs. 40 crore. - There is no mention of raising funds through equity or debt for these CAPEX. - On the topic of listing shares on the National Stock Exchange (NSE), the company stated they will do so once they meet the eligibility criteria, but no timeline or fundraising associated with it was provided. - A proposed bonus issue was mentioned but currently not planned, with a possible revisit in the future. - Overall, no specific new fundraising through debt or equity has been indicated.

- Ongoing CAPEX around Rs. 30 crore for a new plant at Dhule; first phase expected operational by March next year, with impact from FY21. - Future CAPEX planned of Rs. 10 crore next year; total around Rs. 40 crore over coming year. - CAPEX splits between debottlenecking existing capacities and new product lines, particularly pharma intermediates and fine chemicals. - Total CAPEX for future growth, including Dhule unit, could go up to Rs. 90 crore at optimum capacity. - Environmental investment: Rs. 2.5 to Rs. 3 crore planned over two years to upgrade Effluent Treatment Plants (ETP) to achieve zero-discharge. - New product CAPEX aimed at value-added specialty chemicals, contingent on market conditions. - Focus on capacity utilization improvement (currently around 60%) to enhance margins along with capacity expansions. - CAPEX expected to contribute revenue growth and operational efficiencies from FY21 onwards.

- The company expects around 30% revenue growth for the next year (FY20) on a standalone basis. (Page 4) - Consolidated growth could be even higher than standalone. (Page 12) - Volume growth guidance similarly expected to be around 30%. (Page 11) - The company is working to increase capacity utilization from around 60% currently, aiming above 75%, which should improve operational performance and margins over the next 2-3 years. (Page 14) - Incremental revenue from ongoing CAPEX (especially the new plant at Dhule) expected to impact from FY21 onward. (Pages 11-12) - Export revenues are around 50% and are mostly denominated in USD (~95%), offering some translational gains. (Page 15) - Future growth will be driven by product mix improvements, capacity expansion, and new product introductions targeting fine chemicals, specialty chemicals, and pharma intermediates. (Pages 10-13)

- The company expects a revenue growth of around 30% for the next fiscal year (FY20) on a standalone basis, with consolidated growth possibly higher. - EBITDA margin improvement is targeted, aiming for a range of 14% to 16%. - Efforts are ongoing to improve margins through higher capacity utilization and ramping up operations. - Volume growth is expected to remain around 30% going forward. - Incremental CAPEX in the coming years is geared towards new product categories and debottlenecking, potentially leading to better earnings in subsequent years (effects notably visible from FY21 onwards). - Future margin expansion is anticipated but dependent on market conditions and successful penetration of value-added products. - The company aims to sustain EBITDA margins between 5% to 10% historically, with aspirations to improve beyond current levels towards double-digit margins in the long term. - EPS has shown growth, with Q3FY19 EPS at Rs. 2.06 compared to Rs. 1.80 previously, indicating a positive trend.

- The company indicated having a similar or slightly better order book position compared to the last quarter. - During the last quarter, the order book was about Rs. 125 crore to Rs. 150 crore, out of which Rs. 120 crore was already executed. - They expect to maintain or slightly increase this order booking position to cope with demand. - Sales results for the coming period are expected to be similar to the current quarter's performance, maintaining order flow consistency.